

A peer-reviewed version of this preprint was published in PeerJ on 23 September 2014.

[View the peer-reviewed version](https://doi.org/10.7717/peerj.587) (peerj.com/articles/587), which is the preferred citable publication unless you specifically need to cite this preprint.

Park MD, Bhattacharya J, Park K. 2014. Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting. PeerJ 2:e587
<https://doi.org/10.7717/peerj.587>

Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting

Background: Socioeconomic factors and insurance status have not been correlated with differential use of healthcare services in inflammatory bowel disease (IBD). **Aim:** To describe IBD-related expenditures based on insurance and household income with the use of inpatient, outpatient, emergency, and office-based services, and prescribed medications in the United States (US). **Methods:** We evaluated the Medical Expenditure Panel Survey from 1996 to 2011 of individuals with Crohn's disease (CD) or ulcerative colitis (UC). Nationally weighted means, proportions, and multivariate regression models examined the relationships between income and insurance status with expenditures. **Results:** Annual per capita mean expenditures for CD, UC, and all IBD were \$10,364 (N=238), \$7,827 (N=95), and \$9,528, respectively, significantly higher than non-IBD (\$4,314, N=276,372, $p<0.05$). Publicly insured patients incurred the highest costs (\$18,067), over privately insured (\$8,014, $p<0.05$) or uninsured patients (\$5,129, $p<0.05$). Among all IBD patients, inpatient care composed the highest proportion of costs (\$3,392, $p<0.05$). Inpatient costs were disproportionately higher for publicly insured patients. Public insurance had higher odds of total costs than private (OR 2.13, CI 1.08-4.19) or no insurance (OR 4.94, CI 1.26-19.47), with increased odds for inpatient and emergency care. Private insurance had higher costs associated with outpatient care, office-based care, and prescribed medicines. Low-income patients had lower costs associated with outpatient (OR 0.38, CI 0.15-0.95) and office-based care (OR 0.21, CI 0.07-0.62). **Conclusions:** In the US, high inpatient utilization among publicly insured patients is a previously unrecognized driver of high IBD costs. Bridging this health services gap between SES strata for acute care services may curtail direct IBD-related costs.

1 **Differences in Healthcare Expenditures for Inflammatory Bowel Disease by**
2 **Insurance Status, Income, and Clinical Care Setting**

3 **Running Head:** IBD Expenditures by Insurance Status and Income

4 **Michelle D Park, BA¹; Jay Bhattacharya, MD, PhD²; KT Park, MD, MS³**

5 ¹School of Medicine, Stanford University, Stanford, CA

6 ²Department of Medicine; Department of Economics; Center for Health Policy/Primary Care
7 Outcomes Research, Stanford University, Stanford, CA

8 ³Division of Pediatric Gastroenterology, Department of Pediatrics; Center for Health
9 Policy/Primary Care Outcomes Research, Stanford University, Stanford, CA

10 **Grant Support:**

11 Authors acknowledge the generous support of the Stanford Medical Scholars Research Program
12 of Stanford University School of Medicine. KTP is supported by NIH K08 DK094868. JB is
13 supported by CDEHA P30 AG17253 and NIH R21 AG041112. The manuscript contents are
14 solely the responsibility of the authors, performed independent of all funding sources, and do not
15 necessarily represent the official views of the NIH or Stanford University.

16 **Abbreviations:**

17 CD: Crohn's disease

18 FPL: federal poverty line

19 HRQL-CI: health-related quality of life comorbidity index

20 IBD: inflammatory bowel disease

21 MEPS: Medical Expenditures Panel Survey

22 OOP: out-of-pocket

23 OR: odds ratio

24 UC: ulcerative colitis

25 **Corresponding Author:**

26 KT Park

27 750 Welch Rd. Suite 116

28 Palo Alto, CA 94304

29 ktpark@stanford.edu

30 (650) 723-5070

31 **Potential Conflicts of Interest:** None.

32 **Disclosures:** Authors report no conflicts of interest as described by *PeerJ*

33 **Author Contributions:**

34 Michelle D Park, BA – obtaining funding source, planning and conducting the study, collecting
35 and interpreting data, and drafting/editing the manuscript.

36 Jay Bhattacharya, MD, PhD – planning the study, interpreting data, and editing the manuscript.

37 KT Park, MD, MS – obtaining funding source, planning and conducting the study, collecting and
38 interpreting data, and drafting/editing the manuscript.

39 All authors approve the final draft submitted.**ABSTRACT**

40 **Background:** Socioeconomic factors and insurance status have not been correlated with
41 differential use of healthcare services in inflammatory bowel disease (IBD).

42 **Aim:** To describe IBD-related expenditures based on insurance and household income with the
43 use of inpatient, outpatient, emergency, and office-based services, and prescribed medications
44 in the United States (US).

45 **Methods:** We evaluated the Medical Expenditure Panel Survey from 1996 to 2011 of individuals
46 with Crohn's disease (CD) or ulcerative colitis (UC). Nationally weighted means, proportions,
47 and multivariate regression models examined the relationships between income and insurance
48 status with expenditures.

49 **Results:** Annual per capita mean expenditures for CD, UC, and all IBD were \$10,364 (N=238),
50 \$7,827 (N=95), and \$9,528, respectively, significantly higher than non-IBD (\$4,314, N=276,372,
51 $p<0.05$). Publicly insured patients incurred the highest costs (\$18,067), over privately insured
52 (\$8,014, $p<0.05$) or uninsured patients (\$5,129, $p<0.05$). Among all IBD patients, inpatient care
53 composed the highest proportion of costs (\$3,392, $p<0.05$). Inpatient costs were
54 disproportionately higher for publicly insured patients. Public insurance had higher odds of total
55 costs than private (OR 2.13, CI 1.08-4.19) or no insurance (OR 4.94, CI 1.26-19.47), with
56 increased odds for inpatient and emergency care. Private insurance had higher costs associated
57 with outpatient care, office-based care, and prescribed medicines. Low-income patients had
58 lower costs associated with outpatient (OR 0.38, CI 0.15-0.95) and office-based care (OR 0.21,
59 CI 0.07-0.62).

60 **Conclusions:** In the US, high inpatient utilization among publicly insured patients is a previously
61 unrecognized driver of high IBD costs. Bridging this health services gap between socioeconomic
62 strata for acute care services may curtail direct IBD-related costs.

63 **Keywords:** Crohn's disease; ulcerative colitis; health insurance; socioeconomic factors.

64 INTRODUCTION

Inflammatory bowel disease (IBD), consisting of Crohn's disease (CD) and ulcerative colitis (UC), is an especially costly chronic disease affecting nearly one million Americans and increasing in prevalence, with disproportionate increases in racial and ethnic minorities.¹⁻³ IBD is a major chronic disease with per-patient yearly expenditures estimated around \$8,265-\$11,129 for CD, more costly than diabetes, stroke, coronary artery disease, chronic obstructive pulmonary disease, or multiple sclerosis.^{4,5}

IBD care spans a particularly wide range of services from inpatient, outpatient, emergency, and office-based settings, and unequal utilization of necessary services by different patient populations carries the potential to create economic waste, avoidable morbidity, and health disparities.⁶ In addition, increasing use of medical therapeutics for IBD, in particular biologic agents, create new opportunities for costs to rapidly incur.^{7,8}

Race and socioeconomic factors have long been shown to be associated with unequal healthcare access and utilization, with economic and health implications.⁹ As supported by existing literature, we noted a trend for nonwhite, poor, and underinsured patients to utilize less outpatient care and more inpatient care. Black patients utilized less ambulatory care, specialists, and biologics than whites, while exhibiting increased hospitalization rates.¹⁰⁻¹³ Race-related health disparities have also been demonstrated in IBD disease phenotype, surgery rates, type of surgery, perianal fistulizing disease, and extraintestinal manifestations.^{2,14} Lower income was associated with higher rates of CD-related surgery along with higher IBD-related hospitalizations, emergency department (ED) visits, and physician visits.^{8,15} When comparing race against socioeconomic factors, insurance status was a stronger predictor of leaving against medical advice than race.¹⁶ However, many of these studies failed to separate socioeconomic factors from race/ethnicity, and all were limited in scope by focusing either on a few centers or on one clinical care setting, precluding generalizability and comparisons between different types of services.

Of note, few of the current studies on socioeconomic or racial/ethnic differences in IBD contained nationally representative sample sets. The Medical Expenditure Panel Survey (MEPS) is a nationally representative database that samples 15,000 individuals every year.¹⁷ It is possibly the most comprehensive dataset on U.S. health services and expenditures, capturing insurer costs as well as out-of-pocket expenses and including many relevant comorbid diseases.^{4,17}

We aimed to characterize differences in expenditures based on insurance status, income, and race/ethnicity as they may be associated with differential use of inpatient, outpatient, emergency, and office-based services, as well as prescribed IBD medications. We hypothesized that publicly insured, uninsured, and nonwhite patients would utilize disproportionately more acute care as defined by inpatient and emergency services, while privately insured and white patients would utilize disproportionately more non-acute care as defined by outpatient and office-based services, and prescribed medicines.

METHODS

Data

We performed a longitudinal analysis on data from 1996 to 2011 in the Household Component of MEPS, a nationally representative database conducted by the Agency for Healthcare Research and Quality. MEPS collects data on healthcare utilization and expenditures, health status, health insurance coverage, income, employment, and socio-demographic characteristics for the civilian, non-institutionalized population. 15,000 new individuals are sampled each year and followed for two years with in-person interviews, with response rates ranging from 54 to 78%.¹⁸

MEPS utilizes a complex sampling methodology that includes stratification, clustering, multistage selection, and oversampling of certain subgroups including racial/ethnic minorities.¹⁹ Survey weights allow for nationally representative data analyses and the weighting process includes adjustments for nonresponse over time along with calibration to independent population figures from the U.S. Census Bureau's Current Population Survey.^{19,20}

MEPS defines inpatient, emergency, and outpatient visits as occurring in a hospital setting or a facility connected with a hospital.²¹ Outpatient visits are defined as not requiring overnight hospitalization, as opposed to inpatient visits. Office-based events do not occur in a hospital or hospital-connected facility, but can occur in a variety of settings including doctor's or group practice office, medical clinic, surgical center, community health center, walk-in urgent care centers, or laboratory/x-ray facilities.²¹ Thus, both outpatient and office-based care may include general primary care, and both may involve same-day procedures.

Self-reported expenditure data are validated with information from healthcare and pharmaceutical providers. Self-reported medical conditions are mapped by professional coders to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes.²²

Study population and variables

Individuals ages 3-90 with ICD-9-CM codes of 555.x or 556.x were included in this study a priori and defined as having CD or UC, respectively. Individuals lacking person-level weights were excluded.

Demographic data included age, sex, race/ethnicity, and poverty status. Race/ethnicity was encoded as non-Hispanic white (subsequently abbreviated to "white") or non-white, which included black, Hispanic, Asian, Native American, and mixed-race individuals. Poverty status was measured as a binary variable comparing poor patients to not poor patients, with poverty defined as having a family income less than 100% of the federal poverty line (FPL) defined by the U.S. Census Bureau's Current Population Survey.

The health-related quality of life comorbidity index (HRQL-CI) was used to adjust for comorbid conditions. The HRQL-CI is a validated risk adjustment index that outperforms the Charlson comorbidity index when external validation was assessed in MEPS.^{23,24} To form the HRQL-CI, Mukherjee et al. selected 44 adult, gender-neutral, chronic conditions, then identified those significantly associated with the Short Form-12 physical component summary and mental component summary. The resulting two subsets of conditions comprise the HRQL-CI, consisting of a physical component score and a mental component score.²³

Insurance status was measured as a series of binary variables comparing private, public, and no insurance, for individuals who maintained the same insurance category for a full year. The definition of public insurance in MEPS included Medicaid, Medicare, Tricare (U.S. Department of Defense Military Health System), State Children's Health Insurance Program (SCHIP), and other public hospital/physician programs.²² Private insurance was non-public insurance that covered hospital and physician care. Individuals only covered by single-service plans (e.g. drug, dental, or vision plans) were considered uninsured.

IBD-related medications were identified using pharmacy-reported prescription names. We identified immunomodulators—that is, thiopurines (6-mercaptopurine and azathioprine) and methotrexate—anti-tumor necrosis factor (anti-TNF) agents (adalimumab), 5-aminosalicylate agents, prednisone, antibiotics (metronidazole and ciprofloxacin), and other IBD-related medicines (e.g. laxatives, anti-diarrheals, proton pump inhibitors, and histamine H2 receptor antagonists) as identified by gastroenterology-specific clinical judgment.

Statistical analyses

The primary dependent variables were health expenditures—in total and subcategorized into prescribed medicines or mutually-exclusive clinical care settings (inpatient, outpatient, emergency, and office-based). The primary independent variables were insurance status and poverty status. In calculating standard errors, we accounted for the complex sampling design of MEPS using Stata version 12 (Statacorp, College Station, TX). Sampling variances were estimated using Taylor series linearization (delta method).

Means and proportions were used to produce summary statistics. Multivariate logistic regression models examined the likelihood of incurring annual per capita expenditures above the mean for each respective category (total expenditures, prescribed medicines, or specific clinical care settings). The covariates were age, sex, race/ethnicity, and comorbidities as measured by the HRQL-CI.

RESULTS

Characteristics of IBD patients

We identified 238 individuals with CD, 95 with UC, and 276,369 individuals without IBD (Table 1). MEPS only collects information on conditions associated with medical events, so treated prevalence for CD was 0.17% when weighted to the U.S. population and 0.07% for UC. Unless noted, all subsequent values also refer to nationally representative estimates. The mean age was 47 for CD and 44 for UC, and 43% of CD patients and 59% of UC patients were female. Compared to the overall population, patients with IBD were more likely to be white (88% vs. 73%) and less likely to be black and Hispanic (6% and 4% respectively vs. 13% and 13%) (Table 1). Those with IBD were also more likely to be in the highest income bracket of $\geq 400\%$ FPL (48% vs. 39% of the overall population), and more likely to hold private insurance all year (47% vs. 33% of the overall population). The proportions of IBD patients holding public and no insurance were comparable to the overall population. Mean HRQL-CI scores were 2.06 for IBD patients (SE 0.16) and 1.78 for all respondents (SE 0.01).

Direct cost burden of IBD by clinical care setting

Annual per capita mean expenditures for CD, UC, and all IBD were \$10,364, \$7,827, and \$9,528, respectively, each significantly higher than non-IBD expenditures (\$4,314, $p < 0.05$) by \$3-6K more per year (Table 2). Among IBD patients, inpatient mean expenditures (\$3,392, SE 578) composed the highest proportion of direct costs, above outpatient, office-based, emergency, or prescribed medicines ($p < 0.05$) and nearly double the next closest subcategory of office-based expenditures (\$1,705, SE 163) (Table 2; Figure 1). In contrast, emergency expenditures (\$252, SE 53) composed the lowest proportion of direct costs ($p < 0.05$).

In terms of out-of-pocket (OOP) costs, annual per capita mean expenditures for all IBD were again significantly higher than for non-IBD (\$1,061 vs. \$597, $p < 0.05$) (Table 2). Although inpatient costs contributed the greatest amount to total IBD expenditures as described above, when considering OOP costs, inpatient (mean \$48, SE 17) contributed less than outpatient, office-based, and prescribed medicine costs. The greatest OOP contribution came from office-based (mean \$219, SE 28) and prescribed medicine costs (mean \$150, SE 18), while emergency costs contributed the least to OOP expenditures (mean \$29, SE 9).

Direct cost burden of publicly vs. privately insured IBD patients

When examining the effect of insurance status on annual per capita mean expenditures, publicly insured IBD patients had the highest direct costs by over \$10K (\$18,067), over double that of privately insured (\$8,014, $p < 0.05$) and uninsured patients (\$5,129, $p < 0.05$) (Table 3). For those

publicly insured patients, the vast majority of their high expenditures derived from inpatient costs, at 5x or \$7.8K more than the next closest subcategory of office-based costs (mean \$9,790 vs. \$1,941, $p<0.05$) (Table 3; Figure 2A). For privately insured or uninsured patients, however, inpatient costs were not significantly greater than any other subcategories.

When comparing mean expenditures between private and public insurance in each subcategory, only the inpatient subcategory exhibited a significant difference. Publicly insured patients spent 4.5x or \$7.6K more than the privately insured (mean \$9,790 vs. \$2,174, $p<0.05$) (Table 3; Figure 2A). All other clinical settings and prescribed medicine costs were comparable between IBD patients with public and private insurance.

Effects of no insurance and race/ethnicity on IBD expenditures

Due to the small sample size of uninsured IBD patients, mean expenditures by clinical care setting showed little statistical significance against publicly or privately insured patients (Table 3). Office-based visits, however, showed that the uninsured spent significantly less (mean \$529, SE 152) than either the privately insured (mean \$1801, SE 256, $p<0.05$) or the publicly insured (mean \$1941, SE 435, $p<0.05$) by factors of 3.5 and 3.7, respectively (Table 3; Figure 2A).

No relationships were found between mean expenditures for IBD patients and race/ethnicity when comparing white to black patients, white to Hispanic patients, or white to non-white patients.

Disproportionate spending on acute vs. non-acute care by insurance status and income in multivariate analyses

Multivariate logistic regressions paralleled annual per capita mean expenditure trends when examining the effect of insurance status on IBD expenditures. Figure 2B shows that for total expenditures, publicly insured patients had significantly higher odds of spending above the mean than privately insured (OR 2.13, CI 1.08-4.19) and uninsured patients (OR 4.94, CI 1.26-19.47). IBD patients with public insurance were more likely to spend more for acute care, defined as inpatient and emergency visits, compared to private or no insurance. Just as was seen with mean expenditures, the increased spending seen with public insurance was disproportionately due to high inpatient spending (public vs. private OR 2.82, CI 1.30-6.10; public vs. uninsured OR 2.95, CI 1.02-8.54). Emergency spending was also more likely to be above the mean with public insurance compared to private insurance (OR 2.50, CI 1.23-5.06).

In contrast, privately insured IBD patients were more likely to spend more for non-acute care, defined as outpatient visits, office-based visits, and prescribed medicines. For outpatient and office-based care, privately insured patients were significantly more likely to spend above the mean than the uninsured (outpatient OR 7.02, CI 1.39-35.40; office OR 9.69, CI 1.78-52.67), with no significant relationship to public insurance (Figure 2B). For prescribed medicines, private insurance was more likely to spend above the mean than public insurance (OR 2.05, CI 1.08-3.88).

Table 4 shows that poor IBD patients (<100% FPL) were less likely to spend more for non-acute care, compared to not poor IBD patients. Poor patients were significantly less likely to spend above the mean for outpatient (OR 0.38, CI 0.15-0.95) and office-based care (OR 0.21, CI 0.07-0.62). With a low $n=41$ for poor patients, no other significant differences were found between poor and not poor IBD patients for inpatient, emergency, prescribed medicine, or total expenditures.

No relationships were found in multivariate analyses comparing IBD patients' expenditures to race/ethnicity when comparing white to black patients, white to Hispanic patients, or white to

248 non-white patients. No significant relationships were found regardless of whether poverty was
249 included as a covariate or not.

250 DISCUSSION

251 No known study to date correlates socioeconomic or racial/ethnic differences with health
252 expenditures associated with different services and treatments in IBD. This level of expenditure
253 detail is especially important in a disease such as IBD where a wide range of services and
254 treatments and associated costs exist, potentially revealing patterns that total expenditure
255 figures alone fail to capture.^{8,11,13}

256 Using nationally representative data from 1996 to 2011, we determined that mean inpatient
257 expenditures composed the highest proportion of IBD direct costs, above outpatient, emergency,
258 office-based, and prescribed medicine costs. When IBD patients were stratified by insurance
259 status, we found that publicly insured patients spent over double the mean expenditures of
260 privately insured or uninsured patients, with differences of \$10K and \$13K, respectively. A
261 combined analysis of expenditures by subcategories and insurance status revealed that
262 inpatient costs are the overwhelming driver of public insurance's high expenditures (Table 3;
263 Figure 2A). In fact, after stratification by insurance status, privately insured and uninsured
264 patients no longer showed disproportionately higher inpatient costs relative to the other
265 subcategories, contrary to when all insurance groups were considered together in the IBD
266 expenditure analyses of Table 2 and Figure 1.

267 These mean expenditure data suggest that a primary driver of high IBD costs may be specifically
268 localized to inpatient costs of one insurance group—public insurance. In the current climate of
269 healthcare reform and expenditure curtailment, especially among safety net programs such as
270 Medicaid and SCHIP, our data reveal an intriguing source of potential economic waste and
271 suggest a strategy for reducing the public burden of IBD healthcare costs. Further studies should
272 explore the factors contributing to high inpatient utilization among publicly insured patients and
273 evaluate means of reduction. One potential explanation is that publicly insured patients may
274 reside in impoverished neighborhoods with less capacity to perform outpatient procedures,
275 resulting in longer inpatient stays. Nguyen et al. first hypothesized this theory when they found
276 that bowel resection rates decreased for those with Medicare, Medicaid, and the “self-paid.”²⁵

277 Whether high inpatient costs are tied to inadequate outpatient and maintenance care, to
278 unnecessary hospitalizations and overtreatment, or to yet unknown factors, curbing inpatient
279 costs may have the additional benefit of improving health outcomes. Even beyond public
280 insurers and insurees, a detailed understanding of forces driving inpatient utilization may help
281 improve efficiency in IBD care for managed care organizations, hospitals, and their patients.

282 The uninsured were found to have significantly lower mean expenditures for outpatient care than
283 publicly or privately insured patients. Similarly, poor IBD patients (<100% FPL), were less likely
284 to spend above mean values for non-acute care in outpatient and office-based settings, when
285 compared to not poor patients. This trend for the poor and underinsured to utilize less outpatient
286 and office-based care was also seen in studies on the rates of CD-related bowel surgery, the
287 use of laparoscopic subtotal colectomy for UC, and access to urgent ambulatory care follow-up
288 appointments.^{25–28} The privately insured, on the other hand, were more likely to spend above
289 mean values for non-acute care as well as prescribed medicines. We expected privately insured
290 and not poor patients to spend more on non-acute care, perhaps due to a greater ability to pay
291 OOP costs associated with these non-urgent visits. Greater non-acute care spending and less
292 acute care spending may be associated with more desirable health outcomes as well, but those
293 relationships remain to be studied.

Our findings also consistently reaffirm and expand previously published data. Our overall IBD expenditures and treated prevalence estimates approximate the current values in literature. Our annual per capita expenditures of \$10,364 for CD and \$7,827 for UC are within the range of previously published values of \$8,265 and \$11,129 for CD, and \$5,066 and \$7,706 for UC as published by Kappelman and Gunnarsson, respectively.^{4,29} Our treated prevalence values, despite missing IBD patients without medical events due to the nature of MEPS data collection, still approximate disease prevalences in literature.^{5,30,31} This study's averaging of data over the years from 1996 to 2011 also affects the prevalence values, since prevalence rates have been on a steady rise.^{30,31}

The strengths of the MEPS database lies in its in-depth, in-person survey design combined with insurer/employer and medical provider components allowing for an unusually comprehensive single source of nationally representative information covering a broad range of clinical care with high granularity, prescription medicines, other medical conditions, socio-demographic information, and detailed insurer and OOP expenditure data. In comparison, the healthcare access and utilization literature for IBD has been restricted by the abundance of single-center or narrow-scope studies of clinical care-specific databases such as the Nationwide Inpatient Sample (NIS).⁶ No prior study has analyzed IBD healthcare expenditures with respect to insurance status and socio-demographic factors in a nationally representative sample. A limitation of MEPS is the relatively small sample sizes once stratified by variables of interest. We therefore suspect that even more statistically significant and policy-relevant differences may exist that this study lacked enough power to demonstrate; for example, we may have missed a significant difference in inpatient expenditures between poor and not poor IBD patients.

In conclusion, this study presents comprehensive, nationally representative estimates of detailed expenditure data as they relate to disease type, insurance status, and poverty. These findings can inform IBD-related health policy, guide further analysis of inpatient utilization of publicly insured IBD patients as the main driver of IBD spending, and support IBD advocacy and economic research.

References

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EL, Panaccione R, Ghosh S, Barkema HW, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*. 2012 Jan;142(1):46–54.e42; quiz e30.
2. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic whites: characterization of a large North American cohort. *The American Journal of Gastroenterology*. 2006 May;101(5):1012–23.
3. Straus WL, Eisen GM, Sandler RS, Murray SC, Sessions JT. Crohn's disease: does race matter? *The American Journal of Gastroenterology*. 2000;95(2):479–83.

- 332 4. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-
333 of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.
334 *Digestive Diseases and Sciences*. 2012 Jul 12;57(12):3080–91.
- 335 5. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ,
336 Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and
337 ulcerative colitis in the United States. *Clinical Gastroenterology and Hepatology*. 2007
338 Dec;5(12):1424–9.
- 339 6. Sewell JL, Velayos FS. Systematic review: The role of race and socioeconomic factors on
340 IBD healthcare delivery and effectiveness. *Inflammatory Bowel Diseases*. 2013
341 Mar;19(3):627–43.
- 342 7. Swoger JM, Binion DG. Supportive therapy in IBD: what additional diagnoses and conditions
343 must be treated? *Digestive Diseases*. 2010;28(3):452–62.
- 344 8. Benchimol EI, To T, Griffiths AM, Rabeneck L, Guttman A. Outcomes of pediatric
345 inflammatory bowel disease: socioeconomic status disparity in a universal-access
346 healthcare system. *The Journal of Pediatrics*. 2011 Jun;158(6):960–967.e4.
- 347 9. Andrulis DP. Access to care is the centerpiece in the elimination of socioeconomic disparities
348 in health. *Annals of Internal Medicine*. 1998 Sep 1;129(5):412–6.
- 349 10. Sewell JL, Yee HF, Inadomi JM. Hospitalizations are increasing among minority patients with
350 Crohn's disease and ulcerative colitis. *Inflammatory Bowel Diseases*. 2010 Feb;16(2):204–
351 7.
- 352 11. Nguyen GC, LaVeist TA, Harris ML, Wang M-H, Datta LW, Brant SR. Racial disparities in
353 utilization of specialist care and medications in inflammatory bowel disease. *The American*
354 *Journal of Gastroenterology*. 2010 Oct;105(10):2202–8.
- 355 12. Jackson JF, Dhere T, Repaka A, Shaikat A, Sitaraman S. Crohn's disease in an African-
356 American population. *The American Journal of the Medical Sciences*. 2008
357 Nov;336(5):389–92.
- 358 13. Flasar MH, Johnson T, Roghmann M-C, Cross RK. Disparities in the use of
359 immunomodulators and biologics for the treatment of inflammatory bowel disease: A
360 retrospective cohort study. *Inflammatory Bowel Diseases*. 2008;14(1):13–9.
- 361 14. Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel
362 disease. *The American Journal of Gastroenterology*. 2005 Oct;100(10):2254–61.
- 363 15. Nahon S, Lahmek P, Macaigne G, Faurel J-P, Sass C, Howaizi M, Fleury A, Baju A, Locher
364 C, Barjonet G, et al. Socioeconomic deprivation does not influence the severity of Crohn's
365 disease: Results of a prospective multicenter study. *Inflammatory Bowel Diseases*. 2009
366 Apr;15(4):594–8.
- 367 16. Kaplan GG, Panaccione R, Hubbard JN, Nguyen GC, Shaheen AAM, Ma C, Devlin SM,
368 Leung Y, Myers RP. Inflammatory bowel disease patients who leave hospital against
369 medical advice: predictors and temporal trends. *Inflammatory Bowel Diseases*. 2009
370 Jun;15(6):845–51.
- 371 17. Stone CD. The economic burden of inflammatory bowel disease: clear problem, unclear
372 solution. *Digestive Diseases and Sciences*. 2012 Oct 20;57(12):3042–4.

- 373 18. Agency for Healthcare Research and Quality. MEPS-HC response rates by panel [Internet].
374 Rockville, MD; 2013 Nov. Available from:
375 http://meps.ahrq.gov/mepsweb/survey_comp/hc_response_rate.jsp
- 376 19. Machlin S, Yu W, Zodet M. Computing standard errors for MEPS estimates [Internet].
377 Rockville, MD: Agency for Healthcare Research and Quality; 2005 Jan. Available from:
378 http://meps.ahrq.gov/mepsweb/survey_comp/standard_errors.jsp
- 379 20. Agency for Healthcare Research and Quality. MEPS HC-120: 2008 Medical Conditions
380 [Internet]. Rockville, MD; 2010 Nov. Available from:
381 http://meps.ahrq.gov/data_stats/download_data/pufs/h120/h120doc.shtml
- 382 21. Agency for Healthcare Research and Quality. MEPS topics: office-based visits/use/events
383 and expenditures [Internet]. Rockville, MD; 2009 Oct. Available from:
384 http://meps.ahrq.gov/data_stats/MEPS_topics.jsp?topicid=36Z-1
- 385 22. Agency for Healthcare Research and Quality. MEPS-HC summary data tables technical
386 notes [Internet]. Rockville, MD; 2013 Oct. Available from:
387 http://meps.ahrq.gov/mepsweb/survey_comp/hc_technical_notes.shtml#expenditures
- 388 23. Mukherjee B, Ou H-T, Wang F, Erickson SR. A new comorbidity index: the health-related
389 quality of life comorbidity index. *Journal of Clinical Epidemiology*. 2011 Mar;64(3):309–19.
- 390 24. Ou H-T, Mukherjee B, Erickson SR, Piette JD, Bagozzi RP, Balkrishnan R. Comparative
391 performance of comorbidity indices in predicting health care-related behaviors and
392 outcomes among Medicaid enrollees with type 2 diabetes. *Population Health Management*.
393 2012 Aug;15(4):220–9.
- 394 25. Nguyen GC, Bayless TM, Powe NR, Laveist TA, Brant SR. Race and health insurance are
395 predictors of hospitalized Crohn's disease patients undergoing bowel resection.
396 *Inflammatory Bowel Diseases*. 2007 Nov;13(11):1408–16.
- 397 26. Asplin BR, Rhodes KV, Levy H, Lurie N, Crain AL, Carlin BP, Kellermann AL. Insurance
398 status and access to urgent ambulatory care follow-up appointments. *The Journal of the*
399 *American Medical Association*. 2005 Sep 14;294(10):1248–54.
- 400 27. Medicaid Access Study Group. Access of Medicaid recipients to outpatient care. *The New*
401 *England Journal of Medicine*. 1994 May 19;330(20):1426–30.
- 402 28. Greenstein AJ, Romanoff AM, Moskowitz AJ, Sosunov EA, Khaitov S, Egorova NN. Payer
403 status and access to laparoscopic subtotal colectomy for ulcerative colitis. *Diseases of the*
404 *Colon and Rectum*. 2013 Sep;56(9):1062–7.
- 405 29. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA,
406 Finkelstein JA. Direct health care costs of Crohn's disease and ulcerative colitis in US
407 children and adults. *Gastroenterology*. 2008 Dec;135(6):1907–13.
- 408 30. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's
409 disease and ulcerative colitis in a commercially insured US population. *Digestive Diseases*
410 *and Sciences*. 2013 Feb;58(2):519–25.
- 411 31. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's
412 disease in population-based patient cohorts from North America: a systematic review.
413 *Alimentary Pharmacology & Therapeutics*. 2002 Jan;16(1):51–60.

Table 1 (on next page)

Characteristics of IBD Patients

Table 1. Characteristics of IBD Patients

	All respondents (<i>n</i> =276,702)	IBD (<i>n</i> =333)	CD (<i>n</i> =238)	UC (<i>n</i> =95)
Treated Prevalence (no. per 100,000)	--	238	165	73
Female (%)	55	48	43	59
Male (%)	45	52	57	41
Age (mean) (s.e.)	39.2 (0.2)	46.2 (1.3)	47.0 (1.6)	44.4 (1.8)
Age (%)				
0-18	24	4	5	3
19-39	26	31	30	35
40-64	34	51	48	56
65+	17	15	18	7
Race/Ethnicity (%)				
Non-hispanic white	73	88	90	84
Black	13	6	6	7
Hispanic	13	4	2	8
Family income as % of federal poverty line* (%)				
Poor (<100%)	12	9	11	4
Near poor (100% to <125%)	4	3	3	2
Low income (125% to <200%)	13	13	13	13
Middle income (200% to <400%)	31	27	25	30
High income (≥400%)	39	48	47	51
Insurance** (%)				
Private	33	47	42	58
Public	20	16	20	7
Uninsured	8	8	9	6
HRQL-CI (mean) (s.e.)	1.78 (.01)	2.06 (.16)	2.26 (.21)	1.62 (.20)

*As defined by the Current Population Survey. **Defined as maintaining the insurance category for a full year. Values are nationally representative except *n*'s.

Table 2(on next page)

Distribution of Expenditures Across Clinical Care Settings by Diagnosis

Table 2. Distribution of Expenditures Across Clinical Care Settings by Diagnosis

	IBD (<i>n</i> =333)		CD (<i>n</i> =238)		UC (<i>n</i> =95)	
All Expenditures (OOP + Insurer)	Expenditures (mean) (s.e.)	% of Total	Expenditures (mean) (s.e.)	% of Total	Expenditures (mean) (s.e.)	% of Total
Total	9,528 (910)	--	10,364 (1,173)	--	7,827 (1,182)	--
Acute Care						
Inpatient	3,392 (578)	36	3,743 (743)	36	2,722 (810)	35
Emergency	252 (53)	3	283 (73)	3	192 (47)	2
Non-acute Care						
Outpatient	1,180 (237)	12	1,166 (253)	11	1,241 (529)	16
Office-based	1,705 (163)	18	1,892 (212)	18	1,269 (205)	16
Rx Medicines	711 (106)	7	802 (143)	8	471 (97)	6
	IBD (<i>n</i> =333)		CD (<i>n</i> =238)		UC (<i>n</i> =95)	
OOP Expenditures	OOP (mean) (s.e.)	% of Total	OOP (mean) (s.e.)	% of Total	OOP (mean) (s.e.)	% of Total
Total	1,061 (80)	--	1,088 (78)	--	982 (187)	--
Acute Care						
Inpatient	48 (17)	5	58 (24)	5	29 (14)	3
Emergency	29 (9)	3	39 (13)	4	9 (4)	1
Non-acute Care						
Outpatient	99 (32)	9	75 (18)	7	151 (91)	15
Office-based	219 (28)	21	222 (31)	20	182 (36)	19
Rx Medicines	150 (18)	14	169 (24)	15	100 (18)	10

Means are per capita, per year. OOP: out-of-pocket. Values are nationally representative except *n*'s.

Table 3(on next page)

Association Between Insurance Status and Expenditures Across Clinical Care

Table 3. Association Between Insurance Status and Expenditures Across Clinical Care

	Private (n=136)		Public (n=63)		Uninsured (n=26)	
All Expenditures (OOP + Insurer)	Expenditures (mean) (s.e.)	% of Total	Expenditures (mean) (s.e.)	% of Total	Expenditures (mean) (s.e.)	% of Total
Total	8,014 (918)	--	18,067 (3,918)	--	5,129 (1,675)	--
Acute Care						
Inpatient	2,174 (609)	27	9,790 (2,735)	54	2,840 (1,585)	55
Emergency	217 (65)	3	591 (258)	3	235 (73)	5
Non-acute Care						
Outpatient	1,275 (399)	16	1,696 (917)	9	256 (111)	5
Office-based	1,801 (256)	22	1,941 (435)	11	529 (152)	10
Rx Medicines	769 (227)	3	515 (100)	3	430 (194)	8
	Private (n=136)		Public (n=63)		Uninsured (n=26)	
OOP Expenditures	OOP (mean) (s.e.)	% of Total	OOP (mean) (s.e.)	% of Total	OOP (mean) (s.e.)	% of Total
Total	1,063 (128)	--	1,157 (180)	--	1,220 (281)	--
Acute Care						
Inpatient	26 (11)	2	38 (15)	3	77 (48)	6
Emergency	15 (6)	1	47 (38)	4	121 (58)	10
Non-acute Care						
Outpatient	147 (70)	14	49 (21)	4	94 (92)	8
Office-based	281 (49)	26	136 (61)	12	95 (26)	8
Rx Medicines	103 (16)	10	197 (47)	17	286 (170)	23

Means are per capita, per year. OOP: out-of-pocket. Values are nationally representative except n's.

Table 4(on next page)

Association Between Poverty and Expenditures Across Clinical Care Settings

Table 4. Association Between Poverty and Expenditures Across Clinical Care Settings

Poor Patients <100% FPL (n=41)		
	All Expenditures (OR) (95% CI)	OOP Expenditures (OR) (95% CI)
Total	0.67 (0.31-1.48)	0.91 (0.43-1.92)
Acute Care		
Inpatient	1.01 (0.45-2.27)	1.50 (0.58-3.92)
Emergency	2.01 (0.95-4.22)	1.93 (0.63-5.90)
Non-acute Care		
Outpatient	0.38 (0.15-0.95)*	0.40 (0.11-1.42)
Office-based	0.21 (0.07-0.62)*	0.38 (0.15-1.00)
Rx Medicines	0.56 (0.30-1.06)	0.87 (0.39-1.92)

Odds of expenditures above the mean for the respective setting of clinical care for poor vs. not poor (n=292) patients. Adjusted for age, sex, race/ethnicity, and comorbidities. FPL: federal poverty line. OOP: out-of-pocket. Values are nationally representative except n's.

*p<0.05

Figure 1

Distribution of annual per capita mean expenditures across various categories.

IBD patients unless specified non-IBD. Dark gray: total expenditures. Light gray: mutually exclusive clinical care settings. Error bars are 95% confidence intervals.





Figure 2

Distribution of annual per capita / Odds of IBD expenditures

Figure 2A. Distribution of annual per capita mean expenditures for IBD patients across various categories, by insurance status. Error bars are 95% confidence intervals. Figure 2B. Odds of IBD expenditures above the mean for the respective setting of clinical care, between two insurance status groups. Adjusted for age, sex, race/ethnicity, and comorbidities. * $p < 0.05$

A



B

